ASPIC

Munich, Germany

20-22 February, 2025

See more informations here: https://lymphocyte.kenes.com/

Munich, Germany

20-22 February, 2025

See more informations here: https://lymphocyte.kenes.com/

Valdemar Máximo, Arnaud Da Cruz Paula and Paula Soares from the Cancer Signaling & Metabolism group at i3S have always wanted to know more about the genomic profiling of primary and metastatic thyroid cancers. Hence, they decided to meticulously characterize the genomic features of these neoplasms.

O Valdemar Máximo, Arnaud Da Cruz Paula e a Paula Soares do grupo Cancer Signalling & Metabolism do i3S sempre quiseram saber mais sobre o perfil genómico dos tumores primários e metastáticos da tiróide. Deste modo, decidiram caracterizar meticulosamente as particularidades genómicas destas neoplasias.

Lisbon Congress Centre, Praça das Indústrias 1, Lisboa, Portugal

16-19 June, 2024

See more informations here: https://2025.eacr.org/venue

Don't miss the “ASPIC - EACR Joint Symposium” at 10:20 AM on June 16, the first day of the EACR Congress 2025.
Brought to you with the support of our dedicated sponsors: Lilly, ThermoFisher, Amgen and Merck.

Lisbon Congress Centre, Praça das Indústrias 1, Lisboa, Portugal

16-19 June, 2024

See more informations here: https://2025.eacr.org/venue

Don't miss the “ASPIC - EACR Joint Symposium” at 10:20 AM on June 16, the first day of the EACR Congress 2025.
Brought to you with the support of our dedicated sponsors: Lilly, ThermoFisher, Amgen and Merck.

Virtual Event, Worldwide

11 - 12 February 2025

See more informations here: https://eacr.org/conference/boehringer-ingelheim2025?utm_source=eacrnews&utm_medium=email&utm_campaign=vMAP25&utm_content=

More than half of all advanced cancer patients will experience cachexia at any point in their disease. Patients with cancer cachexia often experience unintentional weight loss mainly due to the progressive loss of body fat and skeletal muscle. This metabolic disorder severely impacts patients’ quality of life, treatments, and survival. Although nutritional supplementation is recommended in cancer cachexia patients, this solution is not capable of reversing cachexia symptoms.

Mais de 50% de doentes com cancro em estadios avançados desenvolve casos de caquexia, um síndrome associado à perda não intencional de massa muscular e tecido adiposo. Esta alteração metabólica tem um impacto negativo na qualidade de vida e na capacidade dos doentes receberem terapia, o que contribui para uma redução do seu tempo de sobrevida. Infelizmente, a suplementação nutricional não é capaz de reverter os sintomas associados à caquexia em doentes com cancro.

Authors and Affiliations: